Navigation Links
FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner

WATERTOWN, Mass., Sept. 19, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that Enanta was named by FierceBiotech as one of 2012's Fierce 15.

The annual award, which was announced today during the BioPharm America Conference at the Westin Boston Waterfront Hotel in Boston, was created by FierceBiotech to recognize 15 promising private biotech companies selected from around the world for their potential to have impact on the treatment of human diseases. This is FierceBiotech's tenth annual Fierce 15 selection. Every year, FierceBiotech evaluates hundreds of private companies for the list, which is based on a variety of factors including the strength of each company's technology, partnerships, venture funding and a competitive market position.

"While biotechs have been scrambling in the race to the market with an interferon-free treatment for hepatitis C, Enanta has been building its pipeline of compounds for use in HCV combination therapies," said FierceBiotech Editor John Carroll. "It's struck key partnerships with Abbott and Novartis and has additional unpartnered programs."

"We are honored to be chosen as one of the Fierce 15 and recognized for our work in the infectious disease field—specifically, our work in multiple HCV drug classes designed for use against the hepatitis C virus," commented Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. "Our goal of providing patients with innovative therapies that are safer and more effective than current treatments is what motivates our employees every day."

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with Abbott), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, the company has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a current focus on developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately-held company headquartered in Watertown, Massachusetts. Enanta's news releases and other information are available on the company's website at

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 100,000 top biotech and pharma professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at

Investor Contact
Carol Miceli
Enanta Pharmaceuticals, Inc.

Media Contact
Kari Watson
MacDougall Biomedical Communications

SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
2. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
3. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
4. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
5. Lloyd Library and Museum Names ABCs Blumenthal to New Honorary Advisory Board
6. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
7. Triple-S Management Corporation Announces the Retirement of Socorro Rivas-Rodriguez; Names Pablo Almodovar Scalley as Successor
8. 23andMe Names Andy Page to Board of Directors
9. Biggest Names in Pharmaceutical, Healthcare Industry to Gather for Groundbreaking Event in Parsippany, New Jersey on September 11-12, 2012
10. BioMotiv Launches Novel Drug Development Operation, Names Leadership Team
11. Sapphire Energy Names New Scientific Advisory Board
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is ... 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... wide range of applications such as, but not limited to, biotechnology, biomedical, drug ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Based on its in-depth analysis of the ... with the 2015 Global Frost & Sullivan Award for ... presents this award to the company that has developed ... of the market it serves. The award recognizes the ... on customer base demands, the overall impact it has ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
Breaking Biology News(10 mins):